Myelodysplastic Syndrome Clinical Trial

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Summary

Reduced intensity conditioning (RIC) has been increasingly adopted as a modality to allow preparative conditioning pre-transplant to be tolerated by older adults or those patients that are otherwise unfit for myeloablative conditioning. In this study Reduced intensity conditioning (RIC) conditioning is used and followed by match aploidentical donor peripheral blood stem cell transplantation.

View Full Description

Full Description

The objectives for the study are listed below:

Primary Objectives

-Determine the safety, and feasibility of administration of several dose combinations of conventional T-cells (Tcon) and regulatory T-cells (Treg)

Secondary Objectives

To determine the GVHD-free relapse-free survival (GRFS) post-HCT
To determine the overall survival (OS) post-HCT
To measure the incidence and severity of acute and chronic GVHD

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Recipient Inclusion Criteria

Patients with the following diseases that are histopathologically-confirmed are eligible

Acute myeloid, lymphoid, or mixed phenotype leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi) or beyond first complete remission (CR1) without the presence of minimal residual disease
Acute myeloid, leukemia, or mixed phenotype leukemia that is either:
Not in morphologic CR with bone marrow infiltration by leukemic blasts of ≤10%, or
In morphologic CR with evidence of minimal residual disease positivity by either multiparametric flow cytometric analysis or by a nucleic acid-based technique
Primary refractory acute myeloid, lymphoid, or mixed phenotype leukemia
Chronic myelogenous leukemia (accelerated, blast or second chronic phase)
Myelodysplastic syndromes
Myelofibrosis that is transplant-eligible
Myeloproliferative syndromes
Blastic plasmacytoid dendritic cell neoplasm
Non-Hodgkin lymphoma with poor risk features not suitable for autologous HCT
Match to the patient as follows:

a. For Arm A:

Availability of a 8/8 or 7/8 HLA-matched donor (related or unrelated) defined by Class I (HLA-A, -B, -C) serologic typing (or higher resolution) and Class II (HLA-DRB1) molecular typing.
If the donor is a 7/8 HLA-match, the mismatch must be a permissive allelic mismatch as assessed by an independent HLA and transplantation expert. b. For Arm B:
Availability of a haploidentical donor who is a ≥ 4/8 but <7>
Donor Inclusion Criteria

Age ≥ 18 and ≤ 75 years of age
Karnofsky performance status of ≥ 70% defined by institutional standards
Seronegative for HIV-1 RNA PCR; HIV 1 and HIV 2 ab (antibody); HTLV-1 and HTLV-2 ab; PCR+ or sAg (surface antigen) hepatitis B ; or PCR or sAg negative for hepatitis C; negative for the Treponema palladum antibody Syphillis screen; and negative for HIV-1 and hepatitis C by nucleic acid testing (NAT) within 30 days of apheresis collection.
In the case that T palladum antibody tests are positive, donors must:

Be evaluated and show no evidence of syphilis infection of any stage by physical exam and history Have completed effective antibiotic therapy to treat syphilis Have a documented negative non-treponemal test (such as RPR) or in the case of a positive non-treponemal test must be evaluated by an infectious disease expert to evaluate for alternative causes of test positivity and confirm no evidence of active syphilitic disease e. Match to the patient as follows:

a. Arm A:

Must be a related or unrelated, 8/8 or 7/8-HLA match to recipient at HLAA, -B, -C, and -DRB1. If 7/8 HLA-matched, must be with permissive allelic HLA mismatch as assessed by an independent HLA and transplantation expert. b. Arm B:

Must be a haploidentical donor who is ≥ 4/8 but < 7/8 match at HLA-A, -B,

C, and -DRB1, with at most one mismatch per locus. f. Must be willing to donate PBSC for up two consecutive days g. Female donors of child-bearing potential must have a negative serum or urine beta HCG test within 3 weeks of mobilization h. Capable of undergoing leukapheresis, have adequate venous access, and be willing to undergo insertion of a central catheter should leukapheresis via peripheral vein be inadequate i. Agreeable to 2nd donation of PBPC (or bone marrow harvest) in the event of graft failure j. The donor or legal guardian greater than 18 years of age, capable of signing an IRB approved consent form. k. Meets other criteria for donation as specified by standard NMDP guidelines (NMDP donors) or institutional standards (non-NMDP donors)

Exclusion Criteria:

Recipient Exclusion Criteria

Seropositive for any of the following:

HIV antibodies; hepatitis B surface antigen (sAg); hepatitis C antibodies

Prior myeloablative therapy or hematopoietic cell transplant
Patients deemed candidates for fully myeloablative preparative conditioning regimens
Candidate for autologous transplant
HIV-positive
Active uncontrolled bacterial, viral or fungal infection, defined as currently taking antimicrobial therapy and progression of clinical symptoms.
Uncontrolled CNS disease involvement
Pregnant or a lactating female
Positive serum or urine beta-HCG test in females of childbearing potential within 3 weeks of registration
Psychosocial circumstances that preclude the patient being able to go through transplant or participate responsibly in follow-up care
Known allergy or hypersensitivity to, or intolerance of, tacrolimus
Hematopoietic cell transplantation-specific comorbidity index (HCT-CI) ≥ 5

Positive anti-donor HLA antibodies against a mismatched allele in the selected donor determined by either:

A positive crossmatch of any titer; or
The presence of anti-donor HLA antibody to any HLA locus
Any uncontrolled autoimmune disease requiring active immunosuppressive treatment
Concurrent malignancies or active disease within 1 year, except nonmelanomatous skin cancers that have been curatively resected

Donor Exclusion Criteria

Evidence of active infection
Seropositive for HIV-1 or-2, HTLV-1 or -2
Medical, physical, or psychological reason that would place the donor at increased risk for complications from growth factor or leukapheresis
Lactating female

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 1

Estimated Enrollment:

24

Study ID:

NCT05088356

Recruitment Status:

Recruiting

Sponsor:

Stanford University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Stanford University
Stanford California, 94304, United States More Info
Kathleen Ji
Contact
650-497-8588
[email protected]
Everett Meyer, MD, PhD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 1

Estimated Enrollment:

24

Study ID:

NCT05088356

Recruitment Status:

Recruiting

Sponsor:


Stanford University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.